J.M. 21 y/o female cc: scalp mass
Dec 26, 2015
History of Present Illness
• Slowly enlarging, firm, occasionaly tender mass on R parietoocipital area (3x3cm)
• Consult– A: Hemangioma– P: Excision
14 years PTA
ADMISSION
2 mos PTA
• Recurrence of slowly enlarging mass (5x5cm)
• Consult at UST OPD– Scalp X Ray– Ultrasound of neck
REVIEW OF SYSTEMS
• (-) weight loss, weakness, fatigue• (-) Headache, dizziness, blurring of vision• (-) hearing loss, aural discharge, tinnitus• (-) epistaxis, nasal discharge, sinusitis• (-) hoarseness, mouth sores, dysphagia• (-) dyspnea, cough
PHYSICAL EXAMINATION
• Conscious, coherent, ambulatory, not in distress• BP: 120/80 PR 80bpm RR 18cpm T 36.5°C Wt. 60 kg Ht. 162cm• Warm moist skin, no active dermatoses• Pink palpebral conjunctivae, anicteric sclerae• No naso-aural discharge, non-congested turbinates,
non-tender sinus, buccal mucosa, tonsils not enlarged, no bleeding gums
• Supple neck, (-) palpable cervical Lymph Nodes, no thyromegaly
• Symmetric on chest expansion, (-) retractions, lungs resonant, clear breath sounds
• Adynamic precordium, AB 5th LICS MCL, S1>S2 at the apex, S2>S1 at the base, no murmurs
• Flat abdomen, no organomegaly, (-) rebound tenderness, no masses
• (-) pallor, clubbing, petechiae, ecchymoses• Pulses ++ on all extremities
Merkel’s Cell Carcinoma
• Classified as a neuroendocrine malignancy of the skin.
• Cutaneous small cell undifferentiated carcinoma
• Incidence of 1200 per year in the US • Mortality rate of 33 %
National Cancer Institute. Fact Sheet MERKEL’S CARCINOMA. 2007Merkel Cell Carcinoma: More Deathsbut Still No Pathway to Blame Bianca Lemos and Paul Nghiem. Journal of Investigative Dermatology (2007)
Discussion
• Merkel’s cells located in the basal layer of the epidermis.
• Grossly, the primary tumor presents as a small, red, pink, or blue-violet, non-ulcerated, painless, intradermal nodular mass often located in sun-exposed areas of the skin such as the head and neck
Discussion
• Neuroendocrine markers– Neuron-specific enolase – Chromogranin– Synaptopysin
Merkel cell carcinoma, Virve Koljonen. World Journal of Surgical Oncology 2006
American Joint Committee on Cancer
• Stage I (primary lesion ≤ 2 cm)• Stage II (primary lesion > 2 cm). • Stage III (nodal involvement)• Stage IV disease (metastatic)
Prognosis
• Aggressive course with reported overall 5-year survival rates ranging from 30% to 64%.
• Survival after a diagnosis of MCC is highly dependent on the stage at presentation.
• 90 percent of recurrences occurring within three years of diagnosis
Merkel Cell Carcinoma: A Case Report and Literature Review. Oncology. Medical Journal of Islamic World Academy of Sciences 15:3, 91-94, 2005